GlassScriptPhysician profile
Jared Ryan Whitehead
NPI 1528356367
$5,642.58
in general payments reported to CMS, 2019-2025
45 companies · $716 in 2025
The $716 reported for 2025 was more than what 79% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,539 · 2022: $1,423 · 2023: $1,401 · 2024: $563 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,680.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $746.30 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $676.19 | 2021-2025 | Farxiga, Lokelma, Breztri |
| Lilly USA, LLC | $608.46 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $539.50 | 2021-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $238.05 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $226.94 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Abbott Laboratories | $205.63 | 2021-2024 | Freestyle Libre 3 |
| Recordati_rare_diseases_inc. | $154.68 | 2021-2023 | Signifor Lar, Isturisa |
| Axsome Therapeutics, INC. | $150.69 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $141.03 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $136.50 | 2021-2024 | |
| Corcept Therapeutics | $135.82 | 2021-2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $121.01 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.08 | 2021-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $95.31 | 2021-2022 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $84.63 | 2021-2023 | Nexletol |
| Averitas Pharma INC. | $83.48 | 2023 | Qutenza |
| Ardelyx, INC. | $82.54 | 2024-2025 | Ibsrela |
| Medtronic, INC. | $79.35 | 2021-2023 | Minimed 780g |
| Amarin Pharma, INC. | $78.64 | 2021 | |
| Astellas Pharma US INC | $69.97 | 2023-2024 | Veozah |
| Amryt Pharma Holdings LTD | $69.67 | 2022-2023 | Mycapssa |
| Insulet Corporation | $67.03 | 2021-2024 | Omnipod |
| Exact Sciences Corporation | $66.15 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $61.92 | 2021-2023 | Evenity, Prolia |
| Antares Pharma, INC. | $52.03 | 2021-2023 | Nocdurna, Tlando, Xyosted |
| Tolmar, INC. | $51.32 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.98 | 2022-2025 | Xifaxan, Trulance |
| Endo Pharmaceuticals INC. | $46.65 | 2021-2022 | |
| Eusa Pharma (US) LLC | $43.91 | 2022 | |
| Amneal Pharmaceuticals LLC | $41.36 | 2021-2023 | Unithroid |
| Grt US Holding, INC. | $39.16 | 2022 | |
| Lundbeck LLC | $34.39 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $28.21 | 2022 | |
| Halozyme INC | $26.66 | 2023 | |
| Tandem Diabetes Care, INC. | $26.17 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascendis Pharma Endocrinology INC | $26.09 | 2023 | |
| Vanda Pharmaceuticals INC. | $25.00 | 2025 | Fanapt |
| Ibsa Pharma INC. | $21.64 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.58 | 2021 | |
| Kyowa Kirin, INC. | $18.92 | 2024 | Crysvita |
| Alexion Pharmaceuticals, INC. | $17.45 | 2023 | Strensiq |
| Clarus Therapeutics INC. | $15.57 | 2021 | |
| Glaxosmithkline, LLC. | $14.10 | 2025 | Trelegy Ellipta |
| Arbor Pharmaceuticals, INC. | $13.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Whitehead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.